NRX Pharmaceuticals, Inc. short interest in 2025
In 2025, NRX Pharmaceuticals, Inc.'s disclosed short interest ran from 9.98% of shares outstanding on 15 Jan 2025 to 6.52% on 31 Dec 2025, a change of -3.46 percentage points. The year's high was 9.98% on 15 Jan 2025 and its low 2.77% on 15 Aug 2025, averaging 5.98% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.26 days on 30 Apr 2025. Full history: NRX Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 9.98% (15 Jan 2025)
- End of year
- 6.52% (31 Dec 2025)
- Change
- -3.46 pp
- High
- 9.98% (15 Jan 2025)
- Low
- 2.77% (15 Aug 2025)
- Average
- 5.98%
- Highest days to cover
- 14.26 (30 Apr 2025)
- SEC filings marked
- 7
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 9.98% | 1.00 | |
| 31 Jan 2025 | 8.54% | 1.33 | |
| 14 Feb 2025 | 9.52% | 3.17 | |
| 28 Feb 2025 | 9.67% | 4.54 | |
| 14 Mar 2025 | 6.06% | 5.67 | 10-K filed |
| 31 Mar 2025 | 7.70% | 6.03 | results (8-K) |
| 15 Apr 2025 | 7.36% | 8.35 | |
| 30 Apr 2025 | 7.17% | 14.26 | |
| 15 May 2025 | 6.43% | 3.34 | 10-Q filed |
| 30 May 2025 | 6.44% | 2.90 | results (8-K) |
| 13 Jun 2025 | 6.92% | 3.25 | |
| 30 Jun 2025 | 5.22% | 3.76 | |
| 15 Jul 2025 | 4.62% | 5.46 | |
| 31 Jul 2025 | 3.56% | 4.38 | |
| 15 Aug 2025 | 2.77% | 1.34 | |
| 29 Aug 2025 | 3.21% | 1.15 | 10-Q filed, results (8-K) |
| 15 Sep 2025 | 3.45% | 1.31 | |
| 30 Sep 2025 | 3.85% | 1.90 | |
| 15 Oct 2025 | 4.65% | 2.26 | |
| 31 Oct 2025 | 4.37% | 1.82 | |
| 14 Nov 2025 | 4.83% | 3.03 | 10-Q filed |
| 28 Nov 2025 | 4.49% | 2.90 | |
| 15 Dec 2025 | 6.21% | 3.52 | |
| 31 Dec 2025 | 6.52% | 3.29 |
See also: NRX Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.